During which period of pregnancy do teratogens act in an all or nothing fashion

Teratogens are drugs, chemicals, or even infections that can cause abnormal fetal development. There are billions of potential teratogens, but only a few agents are proven to have teratogenic effects. These effects can result in a baby being born with a birth defect. Approximately 4 to 5 percent of birth defects are caused by exposure to a teratogen.

The majority of agents that people come into contact with aren’t proven teratogens. Talk to your doctor if you’re concerned about being exposed to a particular medication, chemical, or infection during pregnancy.

Researchers believe a teratogen can affect a developing fetus about 10 to14 days after conception.

The best way to reduce the risk of exposure to teratogens during pregnancy is to avoid taking medications when possible and to avoid exposure to the following:

Avoid prolonged stays in whirlpools, steam rooms, or saunas.

Talk to your doctor before you start taking any over-the-counter supplements during pregnancy. Products that claim to be natural may not necessarily be safe to use during pregnancy.

If your doctor orders a test with possible radiation exposure during your pregnancy, they must strongly believe that the risk of exposure is less than the risk of an untreated or undiagnosed condition. In most cases, the lower abdomen can be shielded with a protective apron to prevent exposure.

It isn’t always possible to avoid sick children, and in most cases, exposures only lead to minor illnesses. When you can, it’s best to avoid such exposures while you’re pregnant. Every parent knows that the easiest place to acquire an illness is in a day care center or school, so avoid these locales as much as possible.

Certain infections can be passed from child to adult, including chickenpox, rubella, and cytomegalovirus (CMV). Adults are immune to many of these diseases. In some cases, however, the exposure may result in an infection that can affect the baby while in the womb. If you’ve been exposed to a known viral or bacterial illness, call your doctor right away so they can decide whether a blood test is needed.

Toxoplasmosis is an infection that can be transmitted from cat feces to humans. If you’re pregnant and have a cat, you should minimize your exposure to the litter box as much as possible. Ask someone else in your household to clean the litter box. If you don’t have anyone to help you with the litter, clean the litter box every day to reduce your risk of contracting toxoplasmosis. You don’t need to get rid of your cat.

You should also avoid known teratogens. These include

  • angiotensin converting enzyme (ACE) inhibitors, such as Zestril and Prinivil
  • alcohol
  • aminopterin
  • androgens, such as methyltestosterone (Android)
  • busulfan (Myleran)
  • carbamazepine (Tegretol)
  • chlorobiphenyls
  • cocaine
  • coumarins
  • warfarin (Coumadin)
  • cyclophosphamide (Cytoxan)
  • danazol (Danocrine)
  • diethylstilbestrol (DES)
  • etretinate (Tegison)
  • isotretinoin (Accutane)
  • lead
  • lithium (Eskalith)
  • mercury
  • methimazole (Tapazole)
  • methotrexate (Rheumatrex)
  • penicillamine (Depen, Cuprimine)
  • phenytoin (Dilantin)
  • phenobarbital (Solfoton)
  • propylthiouracil (PTU)
  • prostaglandins
  • radioactive iodine
  • tetracycline (Sumycin)
  • tobacco
  • trimethadione (Tridione)
  • valproic acid (Depakene)

Some of these agents are easy to avoid. Others may be required for a medical condition and are unavoidable. For instance, you may require phenytoin to control your seizures if you’re pregnant and you have epilepsy. Despite the risk of teratogenic effects, you may be better off taking the phenytoin than risking the occurrence of uncontrolled seizures during pregnancy.

If you need treatment with any of the medications that are known teratogens and you’re pregnant, ask your doctor to send you to a geneticist. Geneticists specialize in the effects of teratogens on fetuses and can help you assess your actual risk given a specific exposure. You may also receive a targeted ultrasound evaluation to determine whether the fetus has been affected in some way.

1

Knapp K, Lenz W, Nowack E: Multiple congenital abnormalities. Lancet 2:725, 1962

2

Wilson JG: Environment and Birth Defects. New York, Academic Press, 1973

3

Wilson JG: Differentiation and the reaction of rat embryos to radiation. J Cell Comp Physiol 43:Suppl 1:11, 1954

4

Fraser FC, Fainstat TD: Production of congenital defects in the offspring of pregnant mice treated with cortisone. Pediatrics 8:527, 1951

5

Jacobson BD: Hazards of norethindrone therapy during pregnancy. Am J Obstet Gynecol 84:962, 1962

6

Phelan MC, Pollock JM, Nance WE: Discordant expression of fetal hydantoin syndrome in heteropaternal dizygotic twins. N Engl J Med 307:99, 1982

7

Vessell ES: Genetic and environmental factors affecting drug metabolism in man. Proceedings of the 4th International Congress on Human Genetics Paris, International Congress Series 250, 391, 1972

8

Peer LA, Bryan WH, Strean LP et al: Induction of cleft palate in mice by cortisone and its reduction by vitamins. J Int Coll Surg 30:249, 1958

9

Kimmel CA, Wilson JG, Schumacher HJ: Studies on metabolism and identification of the causative agent in aspirin teratogenesis in the rat. Teratology 4:15, 1971

10

Kalter M: Interplay of intrinsic and extrinsic factors. In: Wilson JG, Warkany J (eds): Teratology: Principles and Techniques, Chicago. University of Illinois Press, 57, 1965

11

Saxen L: Defective regulatory mechanisms in teratogenesis. Int J Gynaecol Obstet 8:798, 1970

12

Simpson JL: Relationship between congenital anomalies and contraception. Adv Contracep 1:3, 1985

13

Sever LE, Mortenson ML: Teratology and the epidemiology of birth defects. In: Gabbe SG, Niebyl JR, Simpson JL (eds): Obstetrics: Normal and Problem Pregnancies. New York, Churchill-Livingstone, 185–214, 1996

14

Wilson JG, Fraser FC (eds): Handbook of Teratology. New York, Plenum, 1979

15

Teratology Society Public Affairs Committee. FDA Classification of drugs for teratogenic risk Teratol 49:446, 1994

16

Doering PL, Boothby LA, Cheok M: Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks. Am J Obstet Gynecol 187:333, 2002

17

Lammer EJ, Chen DT, Hoar RM et al: Retinoic acid embryopathy. N Engl J Med 313:837, 1985

18

Adams J: High incidence of intellectual deficits in 5-year-old children exposed to isotretinoin “in utero”. Teratology 41:614, 1990

19

Dai WS, Hsu M-A, Itri L: Safety of pregnancy after discontinuation of isotretinoin. Arch Dermatol 125:362, 1989

20

Jick SS, Terris BZ, Jick H: First trimester topical tretinoin and congenital disorders. Lancet 341:1181, 1993

21

Geiger JM, Baudin M, Saurat JH: Teratogenic risk with etritinate and acitretin treatment. Dermatology 189:109, 1994

22

Rothman KJ, Moore LL, Singer MR et al: Teratogenicity of high vitamin A intake. N Engl J Med 333:1369, 1995

23

Mills JL, Simpson JL, Cunningham GC et al: Vitamin A and birth defects. Am J Obstet Gynecol 177:31, 1997

24

Kozlowski RD, Steinbrunner JV, MacKenzie AH et al: Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 88:589, 1990

25

Armenti VT, Ahlswede BA, Ahlswede JR et al: National transplantation pregnancy registry: Analysis of outcome/risks of 394 pregnancies in kidney transplant recipients. Transplant Proc 26:2535, 1994

26

Polifka JE, Friedman JM: Teratogen update: Azathioprine and 6-mercaptopurine. Teratol 65:240, 2002

27

Armenti VT, Moritz MJ, Davison JM: Drug safety issues in pregnancy following transplantation and immunosuppression: Effects and outcomes. Drug Saf 19:219, 1998

28

Takahashi N, Nishida H, Hoshi J: Severe B cell depletion in newborns from renal transplant mothers taking immunosuppressive agents. Transplantation 57:1617, 1994

29

Briggs GC, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 339, 2002

30

Wolfe MS, Cordero JF: Safety of chloroquine in chemosuppression of malaria during pregnancy. Br Med J 290:1466, 1985

31

Hart CW, Naunton RF: The ototoxicity of chloroquine phosphate. Arch Otolaryngol 80:407, 1964

32

Levy M, Buskila D, Gladman DD et al: Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 8:174, 1991

33

Zemlickis D, Lishner M, Degendorfer P et al: Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 152:573, 1992

34

Robert E, Guibaud P: Maternal valproic acid and congenital neural tube defects. Lancet 2:937, 1982

35

Rosa FW: Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 324:674, 1991

36

Holmes LB, Harvey EA, Coull BA et al: The teratogenicity of anticonvulsant drugs. N Engl J Med 344:1132, 2001

37

Dansky LV, Rosenblatt DS, Andermann E: Mechanisms of teratogenesis: Folic acid and antiepileptic therapy. Neurology 42:32, 1992

38

Centers for Disease Control: Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep 41:1, 1992

39

Biale Y, Lewenthal H: Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur J Obstet Gynecol Reprod Biol 18:211, 1984

40

Hanson JW, Smith DW: The fetal hydantoin syndrome. J Pediatr 87:285, 1975

41

Gaily E, Granstrom M-L, Hiilesmaa V et al: Minor anomalies in offspring of epileptic mothers. J Pediatr 112:520, 1988

42

Jones KL, Lacro RV, Johnson KA et al: Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320:1661, 1989

43

Strickler SM, Miller MA, Andermann E et al: Genetic predisposition to phenytoin-induced birth defects. Lancet 2:746, 1985

44

Buehler BA, Delimont D, VanWaes M et al: Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 322:1567, 1990

45

Van der Pol MC, Hadders-Algra M, Huisjes JH et al: Antiepileptic medication in pregnancy: Late effects on the children's central nervous system development. Am J Obstet Gynecol 164:121, 1991

46

Scolnik D, Nulman I, Rovet J et al: Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 271:767, 1994

47

Reinisch JM, Sanders SA, Mortensen EL et al: In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 274:1518, 1995

48

Reiff-Eldridge R, Heffner CR, Ephross SA et al: Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: A pharmaceutical company commitment. Am J Obstet Gynecol 182:159, 2000

49

Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 766–769, 2002

50

Tennis P, Eldridge RR: International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine Epilepsia 43:1161, 2002

51

Callaghan N, Garrett A, Goggin T: Withdrawal of anticonvulsant drugs in patients free of seizures for two years. N Engl J Med 318:942, 1988

52

Deblay MF, Vert P, Andre M et al: Transplacental vitamin K prevents haemorrhagic disease of infant of epileptic mother. Lancet 1:1247, 1982

53

Haddow JE, Palomaki GE, Allan WC et al: Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 341:549, 1999

54

Hall JG, Pauli RM, Wilson KM: Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68:122, 1980

55

Sbarouni E, Oakley CM: Outcome of pregnancy in women with valve prostheses. Br Heart J 71:196, 1994

56

deSwiet M, Ward PD, Fidler J et al: Prolonged heparin therapy in pregnancy causes bone demineralization. Br J Obstet Gynaecol 90:1129, 1983

57

Barbour LA, Kick SD, Steiner JF et al: A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170:862, 1994

58

Dahlman TC: Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 168:1265, 1993

59

Nelson-Piercy C, Letsky EA, deSwiet M: Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 176:1062, 1997

60

Casele HL, Laifer SA, Woelkers DA et al: Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 181:1113, 1999

61

Ginsberg JS, Hirsh J: Use of antithrombotic agents during pregnancy. Chest 114:524S, 1998

62

Chan WS, Ray JG: Low molecular weight heparin use during pregnancy: Issues of safety and practicality. Obstet Gynecol Surv 54:649, 1999

63

Tengborn L, Bergqvist D, Matzsch T et al: Recurrent thromboembolism in pregnancy and puerperium: Is there a need for thromboprophylaxis. Am J Obstet Gynecol 160:90, 1989

64

Lao TT, deSwiet M, Letsky E et al: Prophylaxis of thromboembolism in pregnancy: An alternative. Br J Obstet Gynaecol 92:202, 1985

65

Meschengieser SS, Fondevila CG, Santarelli MT et al: Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart 82:23, 1999

66

Iturbe-Alessio I, del Carmen Fonseca M, Mutchinik O et al: Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 315:1390, 1986

67

Mujtaba Q, Burrow GN: Treatment of hyperthyroidism in pregnancy with propylthiouracil and methimazole. Obstet Gynecol 46:282, 1975

68

Wing DA, Millar LK, Koonings PP et al: A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol 170:90, 1994

69

Burrow GN: Thyroid diseases. In: Burrow GN, Ferris TF (eds): Medical Complications During Pregnancy. Philadelphia, WB Saunders, p 229, 1988

70

Mandel SJ, Larsen PR, Seely EW et al: Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 323:91, 1990

71

l'Allemand D, Gruters A, Heidemann P et al: Iodine-induced alterations of thyroid function in newborn infants after prenatal and perinatal exposure to povidone iodine. J Pediatr 102:935, 1983

72

Czeizel A: Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. Reprod Toxicol 3:183, 1988

73

Laegreid L, Olegard R, Wahlstrom J et al: Abnormalities in children exposed to benzodiazepines in utero. Lancet 1:108, 1987

74

Bergman V, Rosa F, Baum C et al: Effects of exposure to benzodiazepine during fetal life. Lancet 340:694, 1992

75

Linden S, Rich CL: The use of lithium during pregnancy and lactation. J Clin Psychiatry 44:358, 1983

76

Weinstein MR, Goldfield MD: Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 132:529, 1975

77

Zalzstein E, Koren G, Einarson T et al: A case-control study on the association between first trimest exposure to lithium and Ebstein's anomaly. Am J Cardiol 65:817, 1990

78

Jacobson SJ, Jones K, Johnson K et al: Prospective multi-centre study of pregnancy outcome after lithium exposure during first trimester. Lancet 339:530, 1992

79

Krause S, Ebbesen F, Lange AP: Polyhydramnios with maternal lithium treatment. Obstet Gynecol 75:504, 1990

80

Ang MS, Thorp JA, Parisi VM: Maternal lithium therapy and polyhydramnios. Obstet Gynecol 76:517, 1990

81

Cohen LS, Friedman MJ, Jefferson JW: A reevaluation of risk of in utero exposure to lithium. JAMA 271:146, 1994

82

Cohen LS, Altshuler LL, Harlow BL et al: Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295:499, 2006

83

Briggs GC, Freeman RK, Jaffe SJ: Drugs in Pregnancy and Lactation. 6th ed. Baltimore, Williams & Wilkins, p 693, 2002

84

Briggs GC, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed. Baltimore, Williams & Wilkins, p 60, 2002

85

Pastuszak A, Schick-Boschetto B, Zuber C et al: Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 269:2446, 1993

86

Goldstein DJ, Corbin LA, Sundell KL: Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 89:713, 1997

87

Nulman I, Rovert J, Stewart DE et al: Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258, 1997

88

Chambers CD, Johnson KA, Dick LM et al: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335:1010, 1996

89

Kulin NA, Pastuszak A, Sage SR et al: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study. JAMA 279:609, 1998

90

Nulman I, Rovet J, Stewart DE et al: Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective controlled study. Am J Psych 159:1889, 2002

91

Hendrick V, Smith LM, Suri R et al: Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 188:812, 2003

92

Louik C, Lin AE, Werler MM et al: First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675, 2007

93

Alwan S, Reefhuis J, Rasmussen SA, et al: Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684, 2007

94

Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354:579, 2006

95

ACOG Committee on Practice Bulletins No. 92, American College of Obstetricians and Gynecologists: Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 111:1001, 2008

96

Sahakian V, Rouse D, Sipes S et al: Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: A randomized double-blind, placebo-controlled study. Obstet Gynecol 78:33, 1991

97

Vutyavanich T, Wongtra-Rjan S, Ruangsri R: Pyridoxine for nausea and vomiting of pregnancy: A randomized double-blind placebo-controlled trial. Am J Obstet Gynecol 173:881, 1995

98

Diggory PLC, Tomkinson JS: Nausea and vomiting in pregnancy: A trial of meclozine dihydrochloride with and without pyridoxine. Lancet 2:370, 1962

99

Heinonen OP, Slone S, Shapiro S: Birth Defects and Drugs in Pregnancy. Littleton, MA, Publishing Sciences Group, 1977

100

Milkovich L, Van Den Berg BJ: An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 125:244, 1976

101

Cartwright EW: Dramamine in nausea and vomiting of pregnancy. West J Surg Obstet Gynecol 59:216, 1951

102

Sorensen HT, Nielsen GL, Christensen K et al: Birth outcomes following maternal use of metoclopramide. Br J Clin Pharmacol 49:264, 2000

103

Sullivan CA, Johnson CA, Roach H et al: A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 174:2565, 1996

104

Safari HR, Fassett MJ, Souter IC et al: The efficacy of methylprednisolone in the treatment of hyperemesis gravidarum: A randomized, double-blind, controlled study. Am J Obstet Gynecol 179:921, 1998

105

Park-Wyllie L, Mazzotta P, Pastuszak A et al: Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology 62:385, 2000

106

Carmichael SL, Shaw GM: Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 86:242, 1999

107

Vutyavanich T, Kraisarin T, Ruangsri R: Ginger for nausea and vomiting in pregnancy: Randomized, double-masked, placebo-controlled trial. Obstet Gynecol 97:577, 2001

108

Fischer-Rasmussen W, Kjaer SK, Dahl C et al: Ginger treatment of hyperemesis gravidarum. Europ J Obstet Gynecol Reprod Biol 138:19, 1990

109

Ruigomez A, Garcia Rodriguez LA, Cattaruzzi C et al: Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 150:476, 1999

110

Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 1321, 2002

111

Pastuszak A, Schick B, D'Alimonte D et al: The safety of astemizole in pregnancy. J Allergy Clin Immunol 98:748, 1996

112

Zierler S, Purohit D: Prenatal antihistamine exposure and retrolental fibroplasia. Am J Epidemiol 123:192, 1986

113

Werler MM, Mitchell AA, Shapiro S: First trimester maternal medication use in relation to gastroschisis. Teratology 45:361, 1992

114

Werler MM, Mitchell AA, Shapiro S: The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 321:1639, 1989

115

Kozer E, Nikfar S, Costei A et al: Aspirin consumption during the first trimester of pregnancy and congenital anomalies: A meta-analysis. Am J Obstet Gynecol 187:1623, 2002

116

Collins E, Turner G: Salicylates and pregnancy. Lancet 2:1494, 1973

117

Stuart JJ, Gross SJ, Elrad H et al: Effects of acetylsalicylic acid ingestion on maternal and neonatal hemostasis. N Engl J Med 307:909, 1982

118

Areilla RA, Thilenius OB, Ranniger K: Congestive heart failure from suspected ductal closure in utero. J Pediatr 75:74, 1969

119

Cowchock FS, Reece EA, Balaban D et al: Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 166:1318, 1992

120

Farquharson RG, Quenby S, Greaves M: Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment. Obstet Gynecol 100:408, 2002

121

Thulstrup AM, Sorensen HT, Nielsen GL et al: Fetal growth and adverse birth outcomes in women receiving prescriptions for acetaminophen during pregnancy. Am J Perinatol 16:321, 1999

122

Waltman T, Tricomi V, Tavakoli FM: Effect of aspirin on bleeding time during elective abortion. Obstet Gynecol 48:108, 1976

123

Rayburn W, Shukla U, Stetson P et al: Acetaminophen pharmacokinetics: Comparison between pregnant and nonpregnant women. Obstet Gynecol 155:1353, 1986

124

Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 685–687, 2002

125

Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 171–172, 2002

126

Tyson HK: Neonatal withdrawal symptoms associated with maternal use of propoxyphene hydrochloride (Darvon). J Pediatr 85:684, 1974

127

Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 1301, 2002

128

Czeizel AE, Rockenbauer M, Sorensen HT et al: Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: A population-based, case-control study. Am J Obstet Gynecol 184:1289, 2001

129

Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 1291–1295, 2002

130

Jarnerot G, Into-Malmberg MB, Esbjorner E: Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol 16:693, 1981

131

Ochoa AG: Trimethoprim and sulfamethoxazole in pregnancy. JAMA 217:1244, 1971

132

Brumfitt W, Pursell R: Double-blind trial to compare ampicillin, cephalexin, co-trimoxazole, and trimethoprim in treatment of urinary infection. Br Med J 2:673, 1972

133

Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed. Baltimore, Williams & Wilkins, p 1394, 2002

134

Czeizel A: A case-control analysis of the teratogenic effects of co-trimoxazole. Reprod Toxicol 4:305, 1990

135

Hernandez-Diaz S, Werler MM, Walker AM et al: Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 343:1608, 2002

136

Hailey FJ, Fort H, Williams JR et al: Foetal safety of nitrofurantoin macrocrystals therapy during pregnancy: A retrospective analysis. J Int Med Res 11:364, 1983

137

Lenke RR, VanDorsten JP, Schifrin BS: Pyelonephritis in pregnancy: A prospective randomized trial to prevent recurrent disease evaluating suppressive therapy with nitrofurantoin and close surveillance. Am J Obstet Gynecol 146:953, 1983

138

Cohlan SQU, Bevelander G, Tiamsic T: Growth inhibition of prematures receiving tetracycline. Am J Dis Child 105:453, 1963

139

Aselton P, Jick H, Mulnsky A et al: First-trimester drug use and congenital disorders. Obstet Gynecol 65:451, 1985

140

Czeizel AE, Rockenbauer M: Teratogenic study of doxycyline. Obstet Gynecol 89:524, 1997

141

Robinson GC, Cambon KG: Hearing loss in infants of tuberculous mothers treated with streptomycin during pregnancy. N Engl J Med 271:949, 1964

142

Nishimura H, Tanimura T: Clinical Aspects of the Teratogenicity of Drugs. Amsterdam, Excerpta Medica, 1976

143

L'Hommedieu CS, Nicholas D, Armes DA et al: Potentiation of magnesium ulfate-induced neuromuscular weakness by gentamicin, tobramycin, and amikacin. J Pediatr 102:629, 1983

144

Marynowski A, Sianozecka E: Comparison of the incidence of congenital malformations in neonates from healthy mothers and from patients treated because of tuberculosis. Ginekol Pol 43:713, 1972

145

Zaske DE, Cipolle RJ, Strate RG et al: Rapid gentamicin elimination in obstetric patients. Obstet Gynecol 56:559, 1980

146

Mitra AG, Whitten MK, Laurent SL et al: A randomized, prospective study comparing once-daily gentamicin versus thrice-daily gentamicin in the treatment of puerperal infection. Am J Obstet Gynecol 177:786, 1997

147

American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 149:1359, 1994

148

Philipson A, Sabath LD, Charles D: Transplacental passage of erythromycin and clindamycin. N Engl J Med 288:1219, 1973

149

South MA, Short DH, Knox JM: Failure of erythromycin estolate therapy in in utero syphilis. JAMA 190:70, 1964

150

Einarson A, Phillips E, Mawji F et al: A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 15:523, 1998

151

Briggs GC, Freeman RK, Jaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 286, 2002

152

Berkovitch M, Pastuszak A, Gazarian M et al: Safety of the new quinolones in pregnancy. Obstet Gynecol 84:535, 1994

153

Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and lactation. 6th ed. Baltimore, Williams & Wilkins, p 270, 2002

154

Piper JM, Mitchel EF, Ray WA: Prenatal use of metronidazole and birth defects: No association. Obstet Gynecol 82:348, 1993

155

Burtin P, Taddio A, Ariburnu O et al: Safety of metronidazole in pregnancy: A meta-analysis. Am J Obstet Gynecol 172:525, 1995

156

Culnane M, Fowler MG, Lee SS et al: Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 281:151, 1999

157

McGowan JP, Crane M, Wiznia AA et al: Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women. Obstet Gynecol 94:641, 1999

158

Watts DH: Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 346:1879, 2002

159

Rosa FW, Baum C, Shaw M: Pregnancy outcomes after first trimester vaginitis drug therapy. Obstet Gynecol 69:751, 1987

160

Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and lactation. 6th ed. Baltimore, Williams & Wilkins, p 300, 2002

161

Pursley TJ, Blomquist IK, Abraham J et al: Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 22:336, 1996

162

Jick SS: Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 19:221, 1999

163

Mastroiacovo P, Mazzone T, Botto LD et al: Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 175:1645, 1996

164

Main EK, Main DM, Gabbe SG: Chronic oral terbutaline therapy is associated with maternal glucose intolerance. Obstet Gynecol 157:644, 1987

165

Weiner CP, Landas S, Persoon TJ: Digoxin-like immunoreactive substance in fetuses with and without cardiac pathology. Am J Obstet Gynecol 157:368, 1987

166

Weiner CP, Thompson MIB: Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. Am J Obstet Gynecol 158:570, 1988

167

Pruyn SC, Phelan JP, Buchanan GC: Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol 135:485, 1979

168

Redmond GP: Propranolol and fetal growth retardation. Semin Perinatol 6:142, 1982

169

Magee LA, Bull SB, Kren G et al: The generalizability of trial data; a comparison of β-blocker trial participants with a prospective cohort of women taking β-blockers in pregnancy. Europ J Obstet Gynecol Reprod Biol 94:205, 2001

170

Lydakis C, Lip GYH, Beevers M et al: Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertension 12:541, 1999

171

Easterling TR, Carr DB, Brateng D et al: Treatment of hypertension in pregnancy: Effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 98:427, 2001

172

Burrows RF, Burrows EA: Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust NZJ Obstet Gynecol 38:3:306, 1998

173

Hanssens M, Keirse MJNC, Vankelecom F et al: Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 78:128, 1991

174

Piper JM, Ray WA, Rosa FW: Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol 80:429, 1992

175

Asch RH, Greenblatt RB: Update on the safety and efficacy of clomiphene citrate as a therapeutic agent. J Reprod Med 17:175, 1976

176

Riuz-Velasco V, Tolis G: Pregnancy in hyperprolactinemic women. Fertil Steril 41:793, 1984

177

Wiseman RA, Dodds-Smith IC: Cardiovascular birth defects and antenatal exposure to female sex hormones: A reevaluation of some base data. Teratology 30:359, 1984

178

Katz Z, Lancet M, Skornik J et al: Teratogenicity of progestagens given during the first trimester of pregnancy. Obstet Gynecol 65:775, 1985

179

Raman-Wilms L, Tseng AL, Wighardt S et al: Fetal genital effects of first-trimester sex hormone exposure: A meta-analysis. Obstet Gynecol 85:141, 1995

180

Wilkins L: Masculinization of female fetus due to use of orally given progestins. JAMA 172:1028, 1960

181

Duck SC, Katayama KP: Danazol may cause female pseudohermaphroditism. Fertil Steril 35:230, 1981

182

Shapiro S, Slone D, Heinonen OP et al: Birth defects and vaginal spermicides. JAMA 247:2381, 1982

183

Mills JL, Reed GF, Nugent RP et al: Are there adverse effects of periconceptional spermicide use. Fertil Steril 43:442, 1985

184

Linn S, Schoenbaum SC, Monson RR et al: Lack of association between contraceptive usage and congenital malformations in offspring. Am J Obstet Gynecol 147:923, 1983

185

Shah NR, Bracken MB: A systematic review and meta-analysis of prospective studies on the association between interval cigarette smoking and preterm delivery. Am J Obstet Gynecol 182:465, 2000

186

Alberman E, Creasy M, Elliott M et al: Maternal factors associated with fetal chromosomal anomalies in spontaneous abortions. J Obstet Gynecol 83:621, 1976

187

Dolan-Mullen P, Ramierez G, Groff JY: A meta-analysis of randomized trials of prenatal smoking cessation interventions. Am J Obstet Gynecol 171:1328, 1994

188

Martin TR, Bracken MB: Association of low birth weight with passive smoke exposure in pregnancy. Am J Epidemiol 124:633, 1986

189

Marcus BH, Albrecht AE, King TK et al: The efficacy of exercise as an aid for smoking cessation in women. Arch Intern Med 159:1229, 1999

190

Tonnesen P, Norregaard J, Simonsen K et al: A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 325:311, 1991

191

Ogburn PL, Hurt RD, Croghan IT et al: Nicotine patch use in pregnant smokers: Nicotine and cotinine levels and fetal effects. Am J Obstet Gynecol 181:736, 1999

192

Jones KL, Smith DW, Ulleland CN et al: Patterns of malformation in offspring of chronic alcoholic mothers. Lancet 1:1267, 1973

193

Rosett HL: A clinical perspective of the fetal alcohol syndrome. Alcohol Clin Exp Res 4:119, 1980

194

Jones KL, Smith DW, Streissguth AP et al: Outcome of offspring of chronic alcoholic women. Lancet 1:1076, 1974

195

Ouellette EM, Rosett HL, Rosman NP et al: Adverse effects on offspring of maternal alcohol abuse during pregnancy. N Engl J Med 297:528, 1977

196

Mills JL, Graubard BI: Is moderate drinking during pregnancy associated with an increased risk of malformations. Pediatrics 80:309, 1987

197

Sokol RJ, Martier SS, Ager JW: The T-ACE questions: Practical prenatal detection of risk-drinking. Am J Obstet Gynecol 160:863, 1989

198

Van den Berg BJ: Epidemiologic observations of prematurity: Effects of tobacco, coffee and alcohol. In: Reed DM, Stanley FJ (eds): The Epidemiology of Prematurity. Baltimore, Urban & Schwarzenberg, 1977

199

Linn S, Schoenbaum SC, Monson RR et al: No association between coffee consumption and adverse outcomes of pregnancy. N Engl J Med 306:141, 1982

200

Martin TR, Bracken MB: The association between low birth weight and caffeine consumption during pregnancy. Am J Epidemiol 126:813, 1987

201

Beaulac-Baillargeon L, Desrosiers C: Caffeine-cigarette interaction on fetal growth. Am J Obstet Gynecol 157:1236, 1987

202

Munoz LM, Lonnerdal B, Keen CL et al: Coffee consumption as a factor in iron deficiency anemia among pregnant women and their infants in Costa Rica. Am J Clin Nutr 48:645, 1988

203

Infante-Rivard C, Fernandez A, Gauthier R et al: Fetal loss associated with caffeine intake before and during pregnancy. JAMA 270:2940, 1993

204

Mills JL, Holmes LB, Aarons JH et al: Moderate caffeine use and the risk of spontaneous abortion and intrauterine growth retardation. JAMA 269:593, 1993

205

Klebanoff MA, Levine RJ, DerSimonian R et al: Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. N Engl J Med 341:1639, 1999

206

Sturtevant FM: Use of aspartame in pregnancy. Int J Fertil 30:85, 1985

207

Finnegan LP, Wapner RJ: Narcotic addiction in pregnancy. In: Niebyl JR (ed): Drug Use in Pregnancy. Philadelphia, Lea & Febiger, p 203, 1988

208

Greenland S, Staisch KJ, Brown N et al: The effects of marijuana use during pregnancy: Part I. A preliminary epidemiologic study Am J Obstet Gynecol 143:408, 1982

209

Fried PA, Buckingham M, Von Kulmiz P: Marijuana use during pregnancy and perinatal risk factors. Am J Obstet Gynecol 146:992, 1983

210

Zuckerman B, Frank DA, Hingson R et al: Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 320:762, 1989

211

Acker D, Sachs BP, Tracey KJ et al: Abruptio placentae associated with cocaine use. Am J Obstet Gynecol 146:220, 1983

212

Little BB, Snell LM, Klein VR et al: Cocaine abuse during pregnancy: Maternal and fetal implications. Obstet Gynecol 73:157, 1989

213

Bingol N, Fuchs M, Diaz V et al: Teratogenicity of cocaine in humans. J Pediatr 110:93, 1987

214

MacGregor SN, Keith LG, Chasnoff IJ et al: Cocaine use during pregnancy: Adverse perinatal outcome. Am J Obstet Gynecol 157:686, 1987

215

Keith LG, MacGregor S, Friedell S et al: Substance abuse in pregnant women: Recent experience at the perinatal center for chemical dependence of Northwestern Memorial Hospital. Obstet Gynecol 73:715, 1989

216

Chasnoff IJ, Griffith DR, MacGregor S et al: Temporal patterns of cocaine use in pregnancy. JAMA 261:1741, 1989

217

Volpe JJ: Effect of cocaine use on the fetus. N Engl J Med 327:399, 1992

218

Handler A, Kistin N, Davis F et al: Cocaine use during pregnancy: Perinatal outcomes. Am J Epidemiol 133:818, 1991

219

Little BB, Snell LM: Brain growth among fetuses exposed to cocaine in utero Asymmetrical growth retardation. Obstet Gynecol 77:361, 1991

220

Chasnoff IJ, Chisum GM, Kaplan WE: Maternal cocaine use and genitourinary tract malformations. Teratology 37:201, 1988

In which timeframe is a pregnancy most susceptible to gross malformation due to teratogenic exposure?

The embryonic period, during which organogenesis takes place, occurs between implantation at around 14 days to around 60 days postconception. This is usually the most sensitive period to teratogenesis when exposure to a teratogenic agent has the greatest likelihood of producing a malformation.

Which medication is teratogen that may cause masculinization of a female fetus?

Etonogestrel Pregnancy Warnings Animal studies have shown that high doses may cause masculinization of female fetuses; doses of this drug up to 2 mg/kg/day (approximately 1.6 to 3 times the human dose) showed no embryotoxic or fetotoxic effects.

In which gestational period is drug therapy associated with a greater incidence?

Nearly 70% of women are taking a medication in the first trimester during organogenesis.

Which category is teratogenic?

Category D Though the benefits of these drugs to mothers may outweigh the risks, there is evidence that they may harm a fetus.